• Castle Biosciences CEO Derek J. Maetzold exercised options for 550 shares at $2.39 on June 15, 2026.
• Maetzold sold 550 shares at $20.66, leaving 21,479 shares held directly.
• He also sold 3,900 shares held through trusts at $20.66, including the Maetzold Descendants 2020 Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-044019), on June 17, 2026, and is solely responsible for the information contained therein.